Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Posts $1M in Q1 Revenue

NEW YORK (GenomeWeb News) – Exact Sciences today reported first-quarter revenues of $1 million compared to $51,000 in the first quarter of 2008.

The primary driver of that growth was license fees of almost $1 million attributable to its recent alliance with Genzyme. The Marlborough, Mass.-based molecular diagnostics firm said that the intellectual property transaction with Genzyme generated $17.2 million in cash, which will be recognized as revenue over 20 quarters as a non-cash allocation.

Exact posted a net loss of $3.8 million, or $.13 per share, compared to a net loss of $2.5 million, or $.09 per share, for the first quarter of 2008.

The company's R&D expenses fell sharply to $108,000 from $859,000 year over year, and its SG&A spending increased to $4.8 million from $1.8 million.

Exact finished the quarter with $3.6 million in cash and cash equivalents, and an additional $17 million in marketable securities.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.